Innovation & Entrepreneurship Champion
Servier, a global leader in oncology governed by a non-profit foundation, approaches innovation with a long-term vision, free of influence from fiduciary responsibilities.
Servier is a leader in oncology and invests 20% of its brand name revenue back into its research and development each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression.
Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. Servier’s team is actively building out this treatment area through collaborations, partnerships and internal research. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.
Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.
For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.us.
Servier FAST Discovery Award
The Servier FAST Discovery Award recognizes the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology and neuroscience, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.
servier’s target therapeutic areas
- Oncology: Cell targeting (e.g., synthetic lethality, precision oncology), specifically across leukemia (AML, ALL, MDS, MPNs), brain, and GI cancers (PDAC, CRC, BTC, Gastric, and Esophageal).
- Neurology: Rare neurological disorders (e.g., familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
- Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
- AI/ML data-driven platforms for drug design (including small molecules, oligonucleotides and antibodies) and to support translational activities (target and biomarker identification)
How to Apply
Your non-confidential application should highlight your innovative approach to advancing therapies for patients with high unmet needs. All submissions will be reviewed by Servier, and one awardee will be selected to receive the Servier FAST Discovery Award, a fast-tracked spot in the Fall 2026 FAST California program. Learn more about FAST California here.
Please direct any questions or comments to Shikha Sharma at [email protected].
Key Dates for 2026 Fall FAST Program
July 6, 2026
Applications Close
August 2026
Servier award winner announced
September 2026
Program kickoff (virtual)
December 10, 2026
innovation showcase (Bay AreA)